Rajesh Asarpota - 30 Jun 2025 Form 4 Insider Report for MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)

Reporting relationship: Chief Financial Officer
Issuer ticker: MRVI
Reported as of: 30 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 Jun 2025, 18:04:51 UTC
Next SEC filing: 22 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Kurt Oreshack, by power of attorney for Rajesh Asarpota

Key filing fact

Rajesh Asarpota filed Form 4 for MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) on 30 Jun 2025.

Key facts

This page summarizes Rajesh Asarpota's Form 4 filing for MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI).
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 30 Jun 2025, 18:04.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001600301 Primary reporting owner

Asarpota Rajesh

Relationship: Chief Financial Officer
Address: C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO
Signature: /s/ Kurt Oreshack, by power of attorney for Rajesh Asarpota
Signature date: 30 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MRVI transaction

Class A Common Stock

Award

Transaction value
Shares: +500,000
Change %
Price
Shares after: 500,000
Date: 30 Jun 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MRVI transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +333,333
Change %
Price: $0.000000
Shares after: 333,333
Date: 30 Jun 2025
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 333,333
Exercise price: $2.41
Footnotes: F2

MRVI transaction Derivative

Performance Stock Units

Award

Transaction value: $0
Shares: +750,000
Change %
Price: $0.000000
Shares after: 750,000
Date: 30 Jun 2025
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 750,000
Exercise price
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan (the "Omnibus Incentive Plan"). Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting. The RSUs vest over a three-year period, with one-third of the RSUs vesting on the first anniversary of the grant date and the remaining two-thirds of the RSUs vesting in 24 substantially equal monthly installments, subject to the Reporting Person's continued employment with the Issuer (except as otherwise provided in connection with certain circumstances as set forth in the award agreement).

Footnote F2

Represents options awarded under the Omnibus Incentive Plan. These options vest over a three-year period, with one-third of the options vesting on the first anniversary of the grant date and the remaining two-thirds of the options vesting in 24 substantially equal monthly installments, subject to the Reporting Person's continued employment with the Issuer (except as otherwise provided in connection with certain circumstances as set forth in the award agreement).

Footnote F3

Represents performance-based restricted stock units ("PSUs") awarded under the Omnibus Incentive Plan. Each PSU represents the contingent right to receive one share of Class A Common Stock of the Issuer. The PSUs will vest if and to the extent the volume-weighted average price of a share of the Class A Common Stock of the Issuer equals or exceeds certain thresholds for the 30 consecutive trading days immediately preceding the third anniversary of the grant date, subject to the Reporting Person's continued employment with the Issuer (except as otherwise provided in connection with certain circumstances as set forth in the award agreement).